The business has 60 years’ experience in the animal health sector with more than 300 product lines marketed in over 120 countries and over 9500 employees. Two thirds of its $4.2 billion revenue in 2011 came from farm animal products.

Within Europe Zoetis™ has three research and development sites at Louvain-la-Neuve and Zaventem in Belgium and Olot in Spain, and manufacturing facilities at Catania and Medolia in Italy as well as Louvain-la-Neuve and Olot. Among the research organisations with which Zoetis is collaborating is the University of Stirling.

The business has been building up its presence in the poultry sector through recent years following the acquisition of Inovoject® with its automated in ovo vaccine delivery devices and last year introduced Poulvac® E-coli, the first spray vaccine against avian pathogenic Escherichia coli (APEC) for the poultry industry to be approved in the European Union.

At the launch of its vision for business in Europe, Africa and the Middle East, Alejandro Bernal, Zoetis executive vice president and area president, stated: "As the largest standalone company in the industry, we are dedicated solely to animal health and focusing on our core business so our customers can grow theirs.

"We strive every day to help customers meet their real-world challenges through quality medicines and vaccines, complemented by diagnostic products, genetic tests and a range of services."

Further Reading

Go to our previous news item on this story by clicking here.